Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology in China, extending intellectual property protection until 2040, which enhances its global patent portfolio and supports future commercialization strategies [1][3]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [5]. Vaccine Technology - The breast cancer vaccine targets human-lactalbumin, a protein linked to lactation that is abnormally expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation without damaging normal tissue [2][4]. Clinical Development - A Phase 1 clinical trial for the breast cancer vaccine has been completed, with full results to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [4]. Intellectual Property Strategy - The newly issued patent reinforces Anixa's intellectual property strategy, allowing for broader international development and commercialization opportunities in regions with high breast cancer incidence [3][4].

Core Insights - Anixa Biosciences has received a Notice of Allowance for a new patent related to its breast cancer vaccine technology from the Chinese National Intellectual Property Administration, expanding its global intellectual property coverage [1][2] - The patent will provide composition of matter protection for the breast cancer vaccine in China, extending IP protection into at least the 2040s [1] - The breast cancer vaccine targets human α-lactalbumin, a protein aberrantly expressed in certain breast cancers, aiming to prime the immune system for tumor prevention [4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [6] - The company’s vaccine platform targets high-incidence cancers and aims to transform cancer prevention strategies [5] - Anixa's business model involves partnerships with renowned research institutions to develop and commercialize innovative cancer therapies [6] Market Context - Breast cancer is the most commonly diagnosed cancer among women in China, with a rising incidence over the past two decades, highlighting the need for innovative preventative solutions like Anixa's vaccine [3] - The new patent complements existing patents in the United States and other jurisdictions, reinforcing Anixa's leadership in cancer immunotherapy [2] - The allowance of the patent strengthens Anixa's ability to pursue strategic global opportunities in regions with high breast cancer burdens [3]

Core Insights - Anixa Biosciences has made significant progress in its clinical and pre-clinical development programs in 2025, maintaining fiscal discipline while advancing its oncology treatment initiatives [1][5] Financial Performance - The company has maintained an average annual cash burn of approximately $5–6 million, which is significantly lower than typical for development-stage biotechnology companies [2] - In the most recent fiscal year, the cash burn was limited to $7 million while advancing two clinical trials [2] - Anixa ended the most recent quarter with over $17 million in cash and no debt, providing more than two years of operational runway [3] Capital Structure - Anixa has a clean capital structure with approximately 32 million common shares outstanding and no warrants [4] - Directors and senior management have consistently purchased stock on the open market, collectively investing millions of dollars, indicating strong belief in the company's long-term value [4] Clinical Programs - The CAR-T therapy program targeting recurrent, platinum-resistant ovarian cancer is progressing, with three dose-escalation cohorts completed in the Phase 1 trial [6][7] - Encouraging signs of efficacy have been observed, with one patient surviving two years post-treatment, significantly exceeding the typical four-month median survival for this population [7] - The breast cancer vaccine, developed in collaboration with Cleveland Clinic, is nearing enrollment completion in its Phase 1 trial, with over 70% of patients showing protocol-defined immune responses [9][11] Future Milestones - Key milestones for the second half of 2025 include final Phase 1 data for the breast cancer vaccine, anticipated FDA interactions, and the initiation of the fourth cohort for the CAR-T ovarian cancer program [15][17] - The company is preparing to extend its vaccine platform to target prostate, lung, and colon cancers, addressing substantial unmet needs in these areas [13][14]